Higher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

Researchers found that higher ocrelizumab exposure over 10 years was associated with less risk of disability progression in ...

Please provide your email address to receive an email when new articles are posted on . Ocrelizumab reduced the number and size of MS-related cortical lesions. Data synthesis featuring a mix of ...

You can also talk with your doctor about the cost of the drug. Ocrevus contains the active ingredient ocrelizumab, and it’s available only as a brand-name biologic drug. It doesn’t come in a ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

Updates on therapies for relapsing-remitting MS from ACTRIMS 2025 include the effects of B-cell-depleting agents in minority populations and a novel approach utilizing CAR T-cells to target CD19.

However, as most data is registry-based and previous trials did not directly compare aHSCT with the most efficacious DMTs, Alemtuzumab, Ocrelizumab, Cladribine and Ofatumumab, questions remain over ...